
35% of Hospitality Workers Avoid Job Ads That Say "We're Like a Family," OysterLink Poll Finds
The results show growing frustration with vague, demanding, or overused language in job postings.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10722/260570_blog_image_template_v1%20(2).jpg
"These phrases are often seen as signals of burnout, low pay, or toxic work environments," said Milos Eric, Co-Founder of OysterLink. "If restaurants and hotels want to attract serious talent, they need to rethink how they write job ads."
OysterLink, a job platform built for restaurant and hospitality workers, is using its community polls to surface what job seekers are really looking for — and what respondents away.
About OysterLink
OysterLink is a job platform for restaurant and hospitality professionals with over 400,000 monthly visitors. OysterLink connects talent with opportunities across the U.S., including the top server jobs in New York City or bartender jobs in Los Angeles.
The platform also offers trend reports, expert insights, and interviews with leaders in hospitality. To explore more data-driven insights or post a job that works for today's talent, visit www.oysterlink.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Toronto Star
an hour ago
- Toronto Star
Luka Doncic agrees to a contract extension through 2028 with the Lakers
LOS ANGELES (AP) — Luka Doncic has agreed to a three-year, US$165 million maximum contract extension with the Los Angeles Lakers, bypassing a chance at free agency next summer to build a long-term future with his new team. The deal keeps Doncic with Los Angeles through 2028. The Slovenian superstar had a player option for the 2026-27 season under his previous contract.


CBC
an hour ago
- CBC
Lawyer breaks down legal fight over Trump's tariffs
U.S. President Donald Trump's use of emergency powers to impose across-the-board tariffs on trading partners came under sharp questioning from federal appellate court judges. Robert Glasgow, partner with McCarthy Tetrault LLP, talks about the legal challenges to Trump's authority to impose tariffs.


Globe and Mail
2 hours ago
- Globe and Mail
AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension
AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase IIb study titled A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2). The study aims to assess the efficacy of AZD3427 in reducing pulmonary vascular resistance in patients with heart failure and pulmonary hypertension over 24 weeks, highlighting its potential significance in treating these conditions. The intervention being tested is AZD3427, administered as a subcutaneous injection. It is designed to target pulmonary hypertension by reducing vascular resistance, with the study evaluating three different dose levels of the drug. The study follows a randomized, parallel assignment model with triple masking, involving participants, care providers, and investigators. Its primary purpose is treatment-focused, aiming to determine the optimal dosing strategy for AZD3427. The study began on April 24, 2023, with an estimated completion date in July 2025. These timelines are crucial for tracking the progress and potential market introduction of AZD3427. The outcome of this study could significantly impact AstraZeneca's market position, potentially boosting its stock performance if results are positive. Investors will be keenly watching for updates, especially in the context of competitive treatments for heart failure and pulmonary hypertension. The study is ongoing, with further details available on the ClinicalTrials portal.